Given the recent finding of therapeutic benefit of ADCs in HER2-low breast cancer in the metastatic setting, identifying potential tumor types that might derive benefit of such approaches in the early-stage setting is of clinical interest. This evidence concerns the gene ERBB2 and breast cancer.